Phase I "Bioactive Lipids: Role in Prostate Cancer Angiogenesis"
Abstract
The goal of DAMD 17-98-1-8502 Idea Development Award is to investigate the role of 12-lipoxygenase (LOX) and its arachidonate product, 12(S)-hydroxyeicosatetraenoic acid (HETE), in human prostate cancer angiogenesis. The research progress during the funding period confirms the role of 12-LOX as a novel "angiogenic switch" governing prostate cancer angiogenesis and tumor growth. We found that 12-LOX increased the angiogenic potential of PCa cells by stimulating the production of VEGF, in addition to its arachidonate product 12(S)-HETE. The link between 12-LOX, a free fatty acid metabolizing enzyme, and VEGF, a putative angiogenic factor, is both novel and exciting, providing significant insights into our understanding of the regulation of VEGF expression during PCa progression. The study also found that 12-LOX and its lipid product, 12(S)-HETE, regulate VEGF expression at transcriptional level. The study also demonstrated the plausibility of using 12-LOX inhibitors such as BMDl88 to inhibit prostate tumor angiogenesis and growth.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA392512
Entities
People
- Kenneth Honn
Organizations
- Wayne State University